Recist Response News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Recist Response. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Recist Response Today - Breaking & Trending Today

Interpreting Results From RAMP 201: Avutometinib +/- Defactinib in Recurrent LGSOC

Published: November 3, 2023

Expert oncologist David M. O’Malley, MD, reviews data from the RAMP 201 study utilizing avutometinib +/- defactinib in patients with recurrent low grade serous ovarian cancer and considers how this combination approach may impact the treatment landscape.

Source: onclive.com

Related Topics:

Expert PerspectivesEmerging TherapiesLow Grade Serous Ovarian CancerOvarian CancerRamp 201Novel TherapyCombination TherapyRecist ResponseEfficacy DataEfficacy OutcomesRamp 301Multidisciplinary CareHealthcare TeamClinical TrialsClinical Trial AccessAccess To Clinical Trials